DCVMN Annual General Meeting (Virtual): Vaccines, a healthy future
3 November 2020 - 5 November 2020
Agenda of the 21st annual meeting
Speakers book 21st annual meeting
PRESENTATIONS
General Meeting presentation materials available for download (PDF):
Tuesday, 3rd November 2020
- Update on NEW VVMs in support of SARS-COV2 vaccine delivery - Temptime
- Re-imagining vaccine manufacturing - Merck
- Aseptic blow-fill-seal fill/finish technology and vaccines - Rommelag
- Tofflon Best Practice for Human Vaccine Manufacturing - Tofflon
- Biozeen approach to steering covid – 19 vaccine manufacturing dynamics - Biozeen
- Considerations for adapting existing facilities to changing vaccine development demands - Bioengineering
- Vaccine Production with GEA pharma separators - GEA
Wednesday, 4rd November 2020
- The ACT Accelerator - The plan, progress & the challenges
- The COVAX Facility and the AMC - GAVI
- COVID vaccines development & manufacturing - CEPI
- UNICEF Procurement for COVID-19 Vaccines - UNICEF
- VIPS: Next steps post prioritisation - VIPS
- Imperial Future Vaccine Manufacturing Research Hub - Imperial College
- Data, decision-making and development - CHAI
- The PAHO COVID-19 Response - PAHO
- Pandemic Response: the critical role of DCVMs - Gates Foundation
Thursday, 5rd November 2020
- IVI’s collaborations to develop new vaccines - IVI
- Regulatory challenges for COVID-19 Vaccine Development - CEPI
- COVID-19 Vaccine: Clinical Trials and Tribulations - Bharat Biotech
- Cross-continent Vaccine Collaboration against COVID-19 - SINOVAC
- Covid-19: Vaccine activities - Biological E.
- Covid-19 Vaccine R&D and CNBG’s Product Portfolio - CNBG
- Manufacture of Covid-19 Vaccine Overview and Challenges - Serum Institute of India
- Regulatory alignment and authorization of vaccines under EUL/PQ - WHO
- Harmonization of regulatory approaches in African countries – WHO efforts - WHO
- 3Rs Improvement of legacy vaccines release testing - Istituto Superiore di Sanità
- Closing Remarks - DCVMN
